A practical reference on Proline-rich sequence: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-26 and is reviewed periodically as new material appears.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
=== Cardiovascular outcomes in type 2 diabetes === A major focus of McGuire's research has been understanding how antihyperglycemic therapies for type 2 diabetes affect cardiovascular risk. His work has helped establish the modern framework of cardiovascular outcome trials (CVOTs), emphasizing the need to demonstrate not only glycemic control but also cardiovascular safety and benefit. He has written on the evolving ethical and scientific challenges of trial design in an era when a number of antihyperglycemic medications have shown cardiovascular protection, advocating for creative trial designs for randomized assessment of novel agents against active comparators with established evidence of efficacy.
== Further reading == Gadd GM, Griffiths AJ (1 December 1977). "Microorganisms and heavy metal toxicity". Microbial Ecology. 4 (4): 303–317. Bibcode:1977MicEc...4..303G. doi:10.1007/BF02013274. ISSN 1432-184X. PMID 24232222. Some microbes tolerate metals that would be toxic to humans.
== Structure == EF-P is a 21 kDa protein encoded by the efp gene. EF-P consists of three β-barrel domains (I, II and III) and has a L shape tRNA structure. Domain II and III of EF-P are similar to each other. Despite the structural similarity of EF-P with tRNA, studies showed that EF-P does not bind to the ribosome at the classical tRNA binding site, but at the distinct position that is located between the P and E sites.
It may be formed by directly fluorinating bromine at room temperature and is purified through distillation. It reacts violently with water and explodes on contact with flammable materials, but is a less powerful fluorinating reagent than chlorine trifluoride. It reacts vigorously with boron, carbon, silicon, arsenic, antimony, iodine, and sulfur to give fluorides, and will also convert most metals and many metal compounds to fluorides; as such, it is used to oxidise uranium to uranium hexafluoride in the nuclear power industry. Refractory oxides tend to be only partially fluorinated, but here the derivatives KBrF4 and BrF2SbF6 remain reactive. Bromine trifluoride is a useful nonaqueous ionising solvent, since it readily dissociates to form BrF2+ and BrF4− and thus conducts electricity. Bromine pentafluoride (BrF5) was first synthesised in 1930. It is produced on a large scale by direct reaction of bromine with excess fluorine at temperatures higher than 150 °C, and on a small scale by the fluorination of potassium bromide at 25 °C. It also reacts violently with water and is a very strong fluorinating agent, although chlorine trifluoride is still stronger.
Sources: en.wikipedia.org
The three substrates of this enzyme are fluoroacetaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are fluoroacetic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is fluoroacetaldehyde:NAD+ oxidoreductase.
In Hungary, a government advisory body recommended mephedrone should be made illegal in August 2010, which was followed, making it illegal in January 2011; Spain followed in February 2011. Mexico, by decree, outlawed mephedrone as a substance "with low or no therapeutical use which pose[s] a serious threat to public health" in 2014. In some countries, mephedrone is not specifically listed as illegal, but is controlled under legislation that makes compounds illegal if they are analogs of drugs already listed. In Australia during 2010, it was not specifically listed as prohibited, but the Australian Federal Police stated it is an analogue to methcathinone and therefore illegal. It is now listed as a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. In February 2010, 22 men were arrested in connection with importing mephedrone. By January 2011, every state in Australia, other than Victoria, had listed it as a controlled drug.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
== Research == His research proposed that peptide hormones are produced from large precursor proteins. In 1967, Chrétien first articulated the prohormone theory, proposing that peptide hormones are produced from larger precursors, a paradigm later widely confirmed and foundational for modern endocrinology. In 1976, his team discovered human β-endorphin, advancing understanding of endogenous opioid systems in pain and stress biology. In 1990, Chrétien and collaborators identified the family of proprotein convertases (PCs/PCSK1–9), endoproteases that activate many precursor proteins and hormones, helping to establish a field often termed “functional endoproteolysis.” A loss-of-function PCSK9 variant characterized in French-Canadian families by Chrétien’s group is associated with markedly low LDL cholesterol and cardioprotection, work that helped validate PCSK9 as a therapeutic target. Chrétien’s prohormone/convertase research has had broad clinical impact, informing therapies and biological understanding in diabetes, obesity, dyslipidemia, atherosclerosis, cancer, opiate use disorders, and Alzheimer’s disease. Between 1981 and 1990, he ranked among the world’s most-cited scientists (reported as seventh globally) reflecting the reach of his contributions.
== History == The company was founded in Bremen on 24 October 1923 as Bremer Flugzeugbau AG by Prof. Henrich Focke, Georg Wulf and Dr. rer. pol. Werner Naumann. Almost immediately, they renamed the company Focke-Wulf Flugzeugbau AG (later Focke-Wulf Flugzeugbau GmbH). Focke-Wulf merged, under government pressure, with Albatros Flugzeugwerke of Berlin in 1931. The Albatros Flugzeugwerke engineer and test pilot Kurt Tank became head of the technical department and started work on the Fw 44 Stieglitz (Goldfinch). Dr Ludwig Roselius became chairman in 1925 and handed over to his brother Friedrich in early 1933. In 1938 Roselius' HAG combine increased its shareholding to 46% and C. Lorenz AG secured 28%. The company was reconstituted as Focke-Wulf Flugzeugbau GmbH and no longer had to publish its accounts. A substantial capital injection occurred at this time. In August 1933 Hans Holle and Rudolf Schubert were given power of attorney over the Berlin branch of Focke-Wulf. Then in October 1933, Focke-Wulf Flugzeugbau A.G. Albatros Berlin was officially registered with the Department of Trade. Dr Roselius always remained the driving force of Focke-Wulf. He and his closest collaborator, Barbara Goette, often met with technical director Professor Kurt Tank. When Roselius died in May 1943, Heinrich Puvogel (later chair of Focke-Wulf) raised 4 million RM and continued handling the financial affairs of Focke-Wulf as chief of Seehandel A.G. Hanna Reitsch demonstrated the Focke-Wulf Fw 61, the first fully controllable helicopter (as opposed to autogyro), in Berlin in 1938.
Sources: en.wikipedia.org
==== Solar cells ==== Graphene has been used on different substrates such as Si, CdS and CdSe to produce Schottky junction solar cells. Through the properties of graphene, such as graphene's work function, solar cell efficiency can be optimized. An advantage of graphene electrodes is the ability to produce inexpensive Schottky junction solar cells.
Aesthetic Theory (1970) The Stars Down to Earth and Other Essays on the Irrational in Culture (1975) Beethoven: The Philosophy of Music; Fragments and Texts (1993) The Psychological Technique of Martin Luther Thomas' Radio Addresses (2000) Kant's 'Critique of Pure Reason' (2002) Current of Music (2006) Aspects of the New Right-Wing Extremism (1969 lecture; first published in English, 2020)
Astrocytes are a sub-type of glial cells in the central nervous system. They are also known as astrocytic glial cells. Star-shaped, their many processes envelop synapses made by neurons. In humans, a single astrocyte can interact with up to two million synapses at a time. Astrocytes are classically identified histologically; many of these cells express glial fibrillary acidic protein (GFAP), a type III intermediate filament protein.
In 19th-century Parisian cafés, upon receiving an order for absinthe, a waiter would present the patron with a dose of absinthe in a suitable glass, sugar, absinthe spoon, and a carafe of iced water. It was up to the patron to prepare the drink, as the inclusion or omission of sugar was strictly an individual preference, as was the amount of water used. As the popularity of the drink increased, additional accoutrements of preparation appeared, including the absinthe fountain, which was effectively a large jar of iced water with spigots, mounted on a lamp base. This lets drinkers prepare several drinks at once – and with a hands-free drip, patrons could socialise while louching a glass. Although many bars served absinthe in standard glassware, several glasses were specifically designed for the French absinthe preparation ritual. Absinthe glasses were typically fashioned with a dose line, bulge, or bubble in the lower portion denoting how much absinthe should be poured. One "dose" of absinthe ranged anywhere around 2–2.5 fluid ounces (60–75 ml). In addition to being prepared with sugar and water, absinthe emerged as a popular cocktail ingredient in both the United Kingdom and the United States. By 1930, dozens of fancy cocktails that called for absinthe had been published in numerous credible bartender guides. One of the most famous of these libations is Ernest Hemingway's "Death in the Afternoon" cocktail, a tongue-in-cheek concoction that contributed to a 1935 collection of celebrity recipes. The directions are: "Pour one jigger absinthe into a Champagne glass.
== IGF-1/GH axis == The IGF "axis" is also commonly referred to as the Growth Hormone/IGF-1 Axis. Insulin-like growth factor 1 (commonly referred to as IGF-1 or at times using Roman numerals as IGF-I) is mainly secreted by the liver as a result of stimulation by growth hormone (GH). IGF-1 is important for both the regulation of normal physiology, as well as a number of pathological states, including cancer. The IGF axis has been shown to play roles in the promotion of cell proliferation and the inhibition of cell death (apoptosis). Insulin-like growth factor 2 (IGF-2, at times IGF-II) is thought to be a primary growth factor required for early development while IGF-1 expression is required for achieving maximal growth. Gene knockout studies in mice have confirmed this, though other animals are likely to regulate the expression of these genes in distinct ways. While IGF-2 may be primarily fetal in action it is also essential for development and function of organs such as the brain, liver, and kidney. Factors that are thought to cause variation in the levels of GH and IGF-1 in the circulation include an individual's genetic make-up, the time of day, age, sex, exercise status, stress levels, nutrition level, body mass index (BMI), disease state, race, estrogen status, and xenobiotic intake. IGF-1 has an involvement in regulating neural development including neurogenesis, myelination, synaptogenesis, and dendritic branching and neuroprotection after neuronal damage. Increased serum levels of IGF-I in children have been associated with higher IQ.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.